Clinical Trials Logo

Urinary Bladder Neoplasms clinical trials

View clinical trials related to Urinary Bladder Neoplasms.

Filter by:

NCT ID: NCT00019435 Completed - Breast Cancer Clinical Trials

LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors

Start date: May 1998
Phase: Phase 1
Study type: Interventional

RATIONALE: The LMB-9 immunotoxin may be able to locate tumor cells and kill them without harming normal cells. This may be an effective treatment for advanced solid tumors. PURPOSE: Phase I trial to study the effectiveness of LMB-9 immunotoxin in treating patients who have advanced solid tumors that have not responded to standard therapy.

NCT ID: NCT00016237 Completed - Lung Cancer Clinical Trials

Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment

Start date: December 2000
Phase: Phase 1
Study type: Interventional

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Interleukin-2 combined with a monoclonal antibody may be an effective treatment for kidney, bladder, or lung cancer. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 combined with a monoclonal antibody in treating patients who have kidney, bladder, or lung cancer that has not responded to previous treatment.

NCT ID: NCT00014534 Completed - Bladder Cancer Clinical Trials

Combination Chemotherapy in Treating Patients With Bladder Cancer

Start date: March 2004
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Randomized phase III trial to compare different combination chemotherapy regimens in treating patients who have advanced bladder cancer.

NCT ID: NCT00014456 Completed - Breast Cancer Clinical Trials

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors

Start date: March 2000
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy plus filgrastim in treating patients who have advanced solid tumors.

NCT ID: NCT00014287 Withdrawn - Bladder Cancer Clinical Trials

Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer

Start date: September 2000
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different ways may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of gemcitabine given directly into the bladder in treating patients who have recurrent or refractory bladder cancer.

NCT ID: NCT00014274 Completed - Bladder Cancer Clinical Trials

Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium

Start date: January 2001
Phase: Phase 2/Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is most effective for transitional cell cancer of the urothelium. PURPOSE: Randomized phase II/III trial to compare different combination chemotherapy regimens in treating patients who have transitional cell cancer of the urothelium.

NCT ID: NCT00014144 Completed - Bladder Cancer Clinical Trials

S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract

Start date: February 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of cancer of the urinary tract. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have advanced cancer of the urinary tract.

NCT ID: NCT00011518 Completed - Bladder Cancer Clinical Trials

Bladder Cancer Case Control Study of Arsenic in Water

Start date: October 1997
Phase: N/A
Study type: Observational

This study is examining the relationship between ingested arsenic and bladder cancer in two areas of California where a large percentage of the population was exposed to drinking water containing arsenic at low to moderate levels.

NCT ID: NCT00009867 Completed - Clinical trials for Transitional Cell Carcinoma of the Bladder

Arsenic Trioxide in Treating Patients With Urothelial Cancer

Start date: December 2000
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have recurrent cancer of the bladder or urinary tract. Arsenic trioxide may kill tumor cells that have become resistant to standard chemotherapy regimens.

NCT ID: NCT00006476 Completed - Bladder Cancer Clinical Trials

Suramin in Treating Patients With Recurrent Bladder Cancer

Start date: October 2000
Phase: Phase 1
Study type: Interventional

RATIONALE: Suramin may stop the growth of bladder cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of suramin in treating patients who have recurrent bladder cancer.